NA-931，Bioglutide

product Introduction:

NA-931 (trade name Bioglutide) is developed by Biomed Industries the world's first quadruple receptor agonist research monomer it is the first cutting-edge scientific research raw material that can simultaneously act on the four metabolic targets of IGF-1, GLP-1, GIP and glucagon. It is mainly used in scientific research experiments and model studies related to human metabolic mechanism and weight factor regulation.

NA-931 is suitable for BMI differentiation body model research, which is suitable for metabolic control experiments of different body mass index samples such as BMI≥ 30kg/m and BMI≥ 27kg/m, and can be applied to multi-dimensional scientific research research on body blood pressure, blood lipid, glucose metabolism, respiratory metabolism, cardiovascular metabolism, etc.

core mechanism of action:

as a novel quadruple receptor agonist monomer, NA 931 can simultaneously activate the four major biological receptors of IGF-1, GLP-1, GIP and glucagon, breaking through the regulatory limitations of traditional single GLP-1 target reagents. NA-931 has excellent blood-brain barrier penetration ability, very low sample dose can activate the body's global metabolic regulation pathway, with ultra-high in vivo bioavailability, greatly improving the effectiveness and stability of target experiments.

Relying on the unique IGF-1 target activation system, NA-931 is different from conventional metabolic research reagents, which can achieve two-way balance of body fat regulation and muscle mass retention, and accurately maintain the stability of lean body mass. At the same time, multi-target synergy disperses metabolic regulation pressure, avoids experimental side effects such as gastrointestinal stress and body discomfort caused by excessive activation of a single target, and builds a metabolic homeostasis research system that is more in line with the native state of the human body.

Common polypeptide problems:

peptide synthesis is used in what way?

Solid phase synthesis technology, liquid phase synthesis technology, microwave synthesis technology and recombinant extension technology. Solid extension can be based on the customer's peptide sequence characteristics, flexible selection of appropriate synthesis technology or combination.

How to deal with problems in peptide synthesis?

Each polypeptide has special properties and sometimes fails to achieve the desired results during synthesis. If due to some special reasons, solid extension cannot successfully deliver polypeptide samples, solid extension technical support personnel will communicate with you in a timely manner.